#Obesity medicine
Chronic weight management as a clinical specialty.
Semaglutide below max dose: real-world data
A Slovak observational study found 11.35% mean weight loss at six months on submaximal semaglutide doses. Below trial figures, but clinically relevant.
GLP-1 drugs in teens: what youth say
A qualitative study of 29 adolescents on GLP-1 and other weight-loss drugs finds families are positive about treatment but uncertain about when to stop.
Tirzepatide after bariatric surgery
An Italian study reports 18.1% weight loss at 24 weeks in 34 post-bariatric patients on tirzepatide. Early data, small sample.
Tirzepatide CV biomarkers in SURMOUNT-1
A SURMOUNT-1 post hoc analysis found tirzepatide reduced CRP, IL-6, leptin, and PAI-1 at 72 weeks. What the biomarker shifts mean, and what they do not.
15-PGDH and muscle loss on GLP-1 drugs
A Stanford mouse study finds that inhibiting 15-PGDH preserved muscle repair during semaglutide weight loss without reducing fat loss.
GLP-1 and GIP drugs in fat cells
A 2026 review maps what GLP-1 and dual GIP/GLP-1 agonists do inside human adipocytes, and finds most evidence still comes from rodent models.
CagriSema vs tirzepatide for obesity
A network meta-analysis of 25 trials ranked tirzepatide 15 mg and CagriSema as the top weight-loss treatments. But direct trial data tells a different story.
DNA-based GLP-1 delivery via MYO Technology
A single injection of plasmid DNA encoding GLP-1 produced sustained weight loss for over a year in obese mice. What the data shows.
GLP-1 drugs and lipedema: early evidence
A 2026 Dermatologic Surgery review found only two studies of GLP-1 receptor agonists in lipedema. The rationale is real, but the clinical evidence is thin.
What Penn Medicine's 'food noise' case study actually showed
Casey Halpern's Nature Medicine case study recorded nucleus-accumbens activity in a single patient on tirzepatide. Activity was suppressed early, then returned at 5 months alongside renewed cravings.
Tirzepatide in the UK: how NICE TA924 and TA1026 shape access
Two NICE technology appraisals decide who gets Mounjaro on the NHS and under what criteria. TA924 covers type-2 diabetes; TA1026 covers obesity. They do not overlap.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.